Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate)
Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method is an FDA-licensed reference biologic from Takeda Pharmaceuticals U.S.A., Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2003
Reference approved
Reference product
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method
Takeda Pharmaceuticals U.S.A., Inc.
- Approved
- Jul 25, 2003
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method, in chronological order.
Reference approval
Approval date of the reference Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method product.
23 yr 2 mo ago
Frequently asked questions
Are there biosimilars approved for Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate)?
No 351(k) biosimilars or interchangeable biosimilars referencing Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.